NanoImaging Services

NanoImaging Services

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

NanoImaging Services is a leading cryo-EM CRO with deep roots in the technology's development, co-founded by pioneers Bridget Carragher and Clint Potter. It operates a high-capacity service model, boasting more transmission electron microscopes than any provider in North America and a strong track record of solving complex protein structures, including membrane proteins and viral vectors. The company serves a broad biopharma clientele, enabling structure-based drug design and nanoparticle analysis without requiring clients to invest in expensive, complex internal infrastructure. Its business is built on making cutting-edge cryo-EM technology accessible and collaborative.

Drug DiscoveryBiologics

Technology Platform

A high-capacity cryo-electron microscopy (cryo-EM) service platform featuring multiple in-house transmission electron microscopes, automated data acquisition software (Leginon heritage), and expert-driven analysis for 3D structural determination of proteins, complexes, and nanoparticles.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The expanding adoption of cryo-EM for challenging drug targets (e.g., membrane proteins) and complex modalities (e.g., PROTACs, AAVs, LNPs) creates a growing market for expert services.
NIS can capitalize by deepening client relationships, expanding into AI-driven analysis, and offering more GMP-compliant services for regulatory submissions.

Risk Factors

Competition is increasing from other CROs and potential in-house capabilities at large pharma.
The business requires continuous, heavy capital investment to keep microscopes and software state-of-the-art.
Revenue is tied to biopharma R&D spending, which is cyclical and sensitive to macroeconomic conditions.

Competitive Landscape

NIS competes with other specialized cryo-EM CROs, academic core facilities offering services, and the in-house capabilities of large pharmaceutical companies. Its key differentiators are its scale (largest microscope fleet in North America per its claim), its foundational expertise from pioneers Carragher and Potter, and its collaborative, senior scientist-led service model.